Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. EMEA Innovative Medicine /
    2. Newsroom/
    3. Neuroscience /
    4. SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder
    Neuroscience

    SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder

    SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder